Ji-jun Yuan

Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant

J. Mu, Jia Wang, Q. Deng, 2020, OncoTargets and therapy.

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease

Xiaofang Wang, Ya-fei Wang, R. Cui, 2021, Frontiers in Immunology.

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review

Yan-yu Jiang, Q. Deng, Qing Li, 2021, Frontiers in Oncology.

Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B‐cell lymphoma and high tumor burden

J. Mu, C. Lyu, Jia Wang, 2022, Hematological oncology.